Sciele Pharma, Inc. Completes Phase III Safety Trial for Glycopyrrolate Liquid, a Treatment for Chronic, Moderate-to-Severe Drooling in Pediatric Patients

ATLANTA--(BUSINESS WIRE)--Sciele Pharma, Inc. (NASDAQ:SCRX) today announced that it has completed its phase III safety trial utilizing a liquid formulation of glycopyrrolate to treat chronic, moderate-to-severe drooling in pediatric patients. This condition often results from cerebral palsy as well as from other neurological disorders. This trial was designed to evaluate safety parameters for glycopyrrolate over a six-month period.